To assess the safety, efficacy and tolerability of escalating doses of KW-6002 as adjunctive therapy to levodopa/carbidopa compared to placebo in patients with Parkinson's Disease and to assess pharmacokinetic data.
Showing the most recent 10 out of 565 publications